

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 January 2006 (05.01.2006)

PCT

(10) International Publication Number
WO 2006/002125 A1

(51) International Patent Classification⁷: **C07D 417/12**,
417/14, A61K 31/4045, A61P 25/28

(74) Agent: **LENCES, Barbara, L.**; Wyeth, Patent Law Department, Five Giralda Farms, Madison, New Jersey 07940 (US).

(21) International Application Number:
PCT/US2005/021852

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 21 June 2005 (21.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/582,290 23 June 2004 (23.06.2004) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **WYETH** [US/US]; Five Giralda Farms, Madison, New Jersey 07940 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **WANG, Youchu** [CN/CA]; 1100 rue Goulet, Apt. 101, Saint-Laurent, Québec H4R 2C6 (CA). **SHAW, Chia-Cheng** [CA/CA]; 730 Saint Germain, Ville Saint-Laurent, Québec H4L 3R5 (CA). **BERNOTAS, Ronald Charles** [US/US]; 908 Morgan Drive, Royersford, Pennsylvania 19468 (US). **WANG, Chung-Chiee Paul** [US/US]; 12 Allen Court, Plainsboro, New Jersey 08536 (US). **CAI, Ping** [US/US]; One Christie Drive, New City, New York 10956 (US). **WANG, Zhi** [CN/US]; 133 Margaret Lane, Malvern, Pennsylvania 19355 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INDOLYLALKYLAMINE METABOLITES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS



(I)

(57) Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT₆ receptor.

**INDOLYLALKYLAMINE METABOLITES AS 5-HYDROXYTRYPTAMINE-6
LIGANDS**

This invention relates to indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands, to pharmaceutical compositions containing them, to methods of treatment using them, and to methods of determining the metabolism of (1-arylsulfonyl-1H-indol-3-yl)ethylamine derivatives using them.

BACKGROUND OF THE INVENTION

Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the neurotransmitter 5-hydroxytryptamine (5-HT) or serotonin. Serotonin is localized in the central and peripheral nervous systems and is known to affect many types of conditions including psychiatric disorders, motor activity, feeding behavior, sexual activity, and neuroendocrine regulation among others. The effects of serotonin are regulated by the various 5-HT receptor subtypes. Known 5-HT receptors include the 5-HT1 family (e.g. 5-HT1A), the 5-HT2 family (e.g. 5-HT2A), 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 subtypes.

The human 5-hydroxytryptamine-6 (5-HT6) receptor subtype has been cloned, and the extensive distribution of its mRNA has been reported. Highest levels of 5-HT6 receptor mRNA have been observed in the olfactory tubercle, the striatum, nucleus accumbens, dentate gyrus and CA1, CA2 and CA3 regions of the hippocampus. Lower levels of 5-HT6 receptor mRNA are seen in the granular layer of the cerebellum, several diencephalic nuclei, amygdala and in the cortex. Northern blots have revealed that 5-HT6 receptor mRNA appears to be exclusively present in the brain, with little evidence for its presence in peripheral tissues. The high affinity of a number of antipsychotic agents for the 5-HT6 receptor, in addition to its mRNA localization *in striatum*, olfactory tubercle and nucleus accumbens suggests that some of the clinical actions of these compounds may be mediated through this receptor. Therefore, 5-HT6 receptor ligands are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorder, attention deficit disorder, migraine, cognitive memory enhancement (e.g. for the treatment of Alzheimer's disease), sleep disorders, feeding

disorders (e.g. anorexia or bulimia), neurodegenerative disorders (e.g. stroke or head trauma), panic attacks, withdrawal from drug abuse (e.g. cocaine, ethanol, nicotine or benzodiazepines), schizophrenia, or the like; or in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome.

5 Indolylalkylamine derivatives such as those described in patent application publication US2003-0171353A-1 are potent and selective 5-HT₆ ligands. Until now, metabolites of said indolylalkylamine derivatives have not been identified, isolated, purified or synthesized.

Therefore, it is an object of this invention to provide compounds which are
10 metabolites of indolylalkylamine 5-HT₆ ligands and which are useful as therapeutic agents in the treatment of a variety of central nervous system disorders related to or affected by the 5-HT₆ receptor.

It is another object of this invention to provide therapeutic methods and pharmaceutical compositions useful for the treatment of central nervous system
15 disorders that are alleviated by 5-HT₆ ligands.

It is a further object of this invention to provide a method to determine the metabolism of an indolylalkylamine derivative.


These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.

20

SUMMARY OF THE INVENTION

The present invention provides a compound of formula I

25



(I)

wherein


Q is CO_2R_5 or $\text{CH}_2\text{NR}_6\text{COR}_7$;

R_1 is H or $\text{C}_1\text{-C}_6$ alkyl;

5 R_2 is an aryl or heteroaryl group each optionally substituted or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

10 R_3 and R_4 are each independently H, halogen, CN, OCO_2R_8 , CO_2R_9 , $\text{CONR}_{10}\text{R}_{11}$, $\text{CNR}_{12}\text{NR}_{13}\text{R}_{14}$, SO_mR_{15} , $\text{NR}_{16}\text{R}_{17}$, OR_{18} , COR_{19} or a $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_3\text{-C}_6$ cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R_5 and R_6 are each independently H or $\text{C}_1\text{-C}_6$ alkyl;

R_7 is $\text{C}_1\text{-C}_6$ alkyl or  ;

m is 0 or an integer of 1 or 2;

15 R_8 , R_9 , R_{15} and R_{19} are each independently H or a $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_3\text{-C}_6$ cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

20 R_{10} , R_{11} and R_{18} are each independently H or a $\text{C}_1\text{-C}_6$ alkyl, aryl or heteroaryl group each optionally substituted; or R_{10} and R_{11} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and

25 R_{12} , R_{13} , R_{14} , R_{16} and R_{17} are each independently H or a $\text{C}_1\text{-C}_4$ alkyl, aryl or heteroaryl group each optionally substituted; or R_{13} and R_{14} or R_{16} and R_{17} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; or

a stereoisomer thereof or a pharmaceutically acceptable salt thereof.


30 The present invention also provides methods and compositions useful for the therapeutic treatment of central nervous system disorders related to or affected by the 5-HT₆ receptor and a method to determine the metabolism of an indolylalkylamine derivative.

DETAILED DESCRIPTION OF THE INVENTION

The ability of the 5-hydroxytryptamine-6 (5-HT₆) receptor to bind a wide range of therapeutic compounds used in psychiatry, coupled with its intriguing distribution in the brain has stimulated significant interest in new compounds which are capable of interacting with or affecting said receptor. Significant efforts are being made to understand the possible role of the 5-HT₆ receptor in psychiatry, cognitive dysfunction, motor function and control, memory, mood and the like. To that end, compounds which demonstrate a binding affinity for the 5-HT₆ receptor are earnestly sought as potential therapeutic agents in the treatment of central nervous system disorders, for example see C. Reavill and D. C. Rogers, Current Opinion in Investigational Drugs, 2001, 2(1):104-109, Pharma Press Ltd.

Indolylalkylamine derivatives having a potent and selective binding affinity for the 5-HT₆ receptor and their preparation are described in patent application publication US2003-0171353A-1, incorporated herein by reference thereto. Until now, metabolites of said indolylalkylamine derivatives have not been identified, isolated, purified or synthesized.

Surprisingly, it has now been found that compounds of formula I are metabolites of indolylalkylamine 5-HT₆ derivatives. Advantageously, said formula I compounds may be used as effective therapeutic agents for the treatment of central nervous system (CNS) disorders associated with or affected by the 5-HT₆ receptor. Accordingly, the present invention provides a compound of formula I



(I)

25

wherein


Q is CO₂R₅ or CH₂NR₆COR₇;

R₁ is H or C₁-C₆alkyl;

R₂ is an aryl or heteroaryl group each optionally substituted or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

5 R₃ and R₄ are each independently H, halogen, CN, OCO₂R₈, CO₂R₉, CONR₁₀R₁₁, CNR₁₂NR₁₃R₁₄, SO_mR₁₅, NR₁₆R₁₇, OR₁₈, COR₁₉ or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₆cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R₅ and R₆ are each independently H or C₁-C₆alkyl;

10 R₇ is C₁-C₆alkyl or  ;

m is 0 or an integer of 1 or 2;


R₈, R₉, R₁₅ and R₁₉ are each independently H or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₆cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

15 R₁₀, R₁₁ and R₁₈ are each independently H or a C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted; or R₁₀ and R₁₁ may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and

20 R₁₂, R₁₃, R₁₄, R₁₆ and R₁₇ are each independently H or a C₁-C₄alkyl, aryl or heteroaryl group each optionally substituted; or R₁₃ and R₁₄ or R₁₆ and R₁₇ may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; or


25 a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

As used in the specification and claims, the term halogen designates Br, Cl, I or F. The term cycloheteroalkyl designates a five- to seven-membered cycloalkyl ring system containing 1 or 2 heteroatoms, which may be the same or different, selected from N, O or S and optionally containing one double bond. Exemplary of
30 the cycloheteroalkyl ring systems included in the term as designated herein are the following rings wherein X is NR, O or S; and R is H or an optional substituent as described hereinbelow:



Similarly, as used in the specification and claims, the term heteroaryl designates a five- to ten-membered aromatic ring system containing 1, 2 or 3
 5 heteroatoms, which may be the same or different, selected from N, O or S. Such heteroaryl ring systems include pyrrolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furyl, thienyl, quinolinyl, isoquinolinyl, indolyl, benzothieryl, benzofuranyl, benzisoxazolyl or the like. The term aryl designates a carbocyclic aromatic ring system e.g. of 6-14
 10 carbon atoms, such as phenyl, naphthyl, anthracenyl or the like. The term haloalkyl as used herein designates a C_nH_{2n+1} group having from one to $2n+1$ halogen atoms which may be the same or different and the term haloalkoxy as used herein designates an OC_nH_{2n+1} group having from one to $2n+1$ halogen atoms which may be the same or different.

Exemplary of the 8- to 13-membered bicyclic or tricyclic ring systems having a
 15 N atom at a bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S included in the term as designated herein are the following ring systems wherein W is NR, O or S; and R is H or an optional substituent as described hereinbelow:



In the specification and claims, when the terms

- C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_7 cycloalkyl, cycloheteroalkyl, aryl,
 5 heteroaryl or 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead are designated as being optionally substituted, the substituent groups which are optionally present may be one or more, e.g. two or three, the same or different of those customarily employed in the development of pharmaceutical compounds or the modification of such compounds to influence their
 10 structure/activity, persistence, absorption, stability or other beneficial property. Specific examples of such substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl,
 15 benzyloxy, heteroaryl, cycloheteroalkyl or cycloalkyl groups, preferably halogen atoms or C_1 - C_6 alkyl groups. Typically, 0-3 substituents, the same or different, may


be present. When any of the foregoing substituents represents or contains an alkyl substituent group e.g. alkoxy, alkanoyl, this may be linear or branched and may contain up to 12, preferably up to 6, more preferably up to 4 carbon atoms.

Pharmaceutically acceptable salts may be any acid addition salt formed by a
5 compound of formula I and a pharmaceutically acceptable acid such as phosphoric, sulfuric, hydrochloric, hydrobromic, citric, maleic, malonic, mandelic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the like.


Compounds of the invention include amides, esters, carbamates or other
10 conventional prodrug forms, which in general, are functional derivatives of the compounds of the invention and which are readily converted to the inventive active moiety *in vivo*. Correspondingly, the method of the invention embraces the treatment of the various conditions described hereinabove with a compound of formula I or with a compound which is not specifically disclosed but which, upon administration,
15 converts to a compound of formula I *in vivo*. Also included are metabolites of the compounds of the present invention defined as active species produced upon introduction of these compounds into a biological system.

When a compound of formula I contains one or more chiral centers or asymmetric carbons, then said formula I compound may exist as one or more
20 stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich or
25 selectively prepare said stereoisomers. Accordingly, the present invention comprises compounds of Formula I, the stereoisomers thereof and the pharmaceutically acceptable salts thereof. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active form.

Preferred compounds of the invention are those compounds of formula I
30 wherein R₁, R₃ and R₄ are H. Also preferred are those compounds of formula I wherein R₂ is an imidazolyl or imidazothiazolyl group each optionally substituted. Another group of preferred compounds of formula I are those compounds wherein Q



- 5 More preferred compounds of the invention are those compounds of formula I wherein R_1 , R_3 and R_4 are H and R_2 is an imidazolyl or imidazothiazolyl group each optionally substituted. Another group of more preferred compounds are those compounds of formula I wherein R_1 , R_3 and R_4 are H; R_2 is an imidazolyl or imidazothiazolyl group each optionally substituted; and Q is



10


Among the preferred compounds of the invention are:

- N-(2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)acetamide;
 1-O-[(2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)amino]carbonyl]-beta-D-glucopyranuronic acid;
 15 {1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}acetic acid;
 N-[(1-{[4-chloro-2-(methylthio)-1H-imidazol-5-yl]sulfonyl}-1H-indol-3-yl)methyl]acetamide; a stereoisomer thereof; or a pharmaceutically acceptable salt thereof.

- 20 Compounds of the invention may be conveniently prepared using conventional synthetic methods and, if required, standard separation and isolation techniques. For example, compounds of formula I wherein Q is CO_2R_5 (Ia) may be prepared by sequentially reacting an indole derivative of formula II with a strong base, such as n-butyllithium, KOt-Bu or NaH , and an arylsulfonyl halide, ClSO_2R_2 .


- 25 The reaction is shown in flow diagram I.

Flow Diagram I



Compounds of formula I wherein Q is $\text{CH}_2\text{NR}_6\text{COR}_7$ and R_7 is $\text{C}_1\text{-C}_6\text{alkyl}$ (Ib) may be prepared by reacting a compound of formula III with an anhydride of formula IV in the presence of a base, such as $\text{N}(\text{C}_2\text{H}_5)_3$ and optionally in the presence of a catalytic amount of 4-dimethylaminopyridine (DMAP). The reaction is shown in flow diagram II.


Flow Diagram II



10

Compounds of formula I wherein Q is O-glucopyranuronic acid (Ic) may be prepared by reacting the compound of formula III with di-t-butyldicarbonate $[(\text{Boc})_2\text{O}]$ and CH_3CN in the presence of a catalytic amount of DMAP to form the isocyanate of formula IV *in situ* and reacting said isocyanate with an hydroxyglucuronic ester of formula V to give the carbamoyl ester of formula VI and hydrolyzing said ester with a base, such as LiOH , to give the desired compound of formula Ic. The reaction sequence is shown in flow diagram III wherein Ac represents COCH_3 .

20

Flow Diagram III

5

Compounds of formula II may be obtained from commercial sources or may be readily prepared using known synthetic methods, for example Baldi, B. G., et al, *Journal of Labelled Compounds and Radiopharmaceuticals* (1985), 22(3), 279-285 or Samizu, K. and Ogasawara, K., *Synlett* (1994), (7), 499-500.

10

Compounds of formula III and their preparation are described in US 2003-0171353A-1, US 6,187,805 and US 6,403,808.

Alternatively, compounds of formula I may be obtained by providing an indolylalkylamine derivative, such as the compound of formula III, to a mammalian test subject and isolating the formula I compound from the plasma of said subject.

Advantageously, the formula I compounds of the invention are useful in the treatment of central nervous system disorders relating to or affected by the 5-HT₆ receptor such as anxiety disorders, mood, psychiatric, cognitive or neurodegenerative disorders, or the like, for example, Alzheimer's disease, attention deficit disorder, acute anxiety disorder, general anxiety disorder, epilepsy, depression, obsessive compulsive disorder, migraine, sleep disorders, neurodegenerative disorders (such as head trauma or stroke), feeding disorders (such as anorexia or bulimia), schizophrenia, memory loss, disorders associated with withdrawal from drug or nicotine abuse, or the like or certain gastrointestinal disorders such as irritable bowel syndrome. Accordingly, the present invention provides a method for the treatment of a disorder of the central nervous system (CNS) related to or affected by the 5-HT₆ receptor in a patient in need thereof which comprises providing said patient a therapeutically effective amount of a compound of formula I as described hereinabove. The compounds may be provided by oral or parenteral administration or in any common manner known to be an effective administration of a therapeutic agent to a patient in need thereof.

The therapeutically effective amount provided in the treatment of a specific CNS disorder may vary according to the specific condition(s) being treated, the size, age and response pattern of the patient, the severity of the disorder, the judgment of the attending physician and the like. In general, effective amounts for daily oral administration may be about 0.01 to 1,000 mg/kg, preferably about 0.5 to 500 mg/kg and effective amounts for parenteral administration may be about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg.

In actual practice, the compounds of the invention are provided by administering the compound or a precursor thereof in a solid or liquid form, either neat or in combination with one or more conventional pharmaceutical carriers or excipients. Accordingly, the present invention provides a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I as described hereinabove.

Solid carriers suitable for use in the composition of the invention include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aides, binders, tablet-disintegrating agents or encapsulating materials. In powders, the carrier may be a finely divided

solid which is in admixture with a finely divided compound of formula I. In tablets, the formula I compound may be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. Said powders and tablets may contain up to 99% by weight of the formula I compound.

- 5 Solid carriers suitable for use in the composition of the invention include calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

- Any pharmaceutically acceptable liquid carrier suitable for preparing
- 10 solutions, suspensions, emulsions, syrups and elixirs may be employed in the composition of the invention. Compounds of formula I may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a pharmaceutically acceptable oil or fat, or a mixture thereof. Said liquid composition may contain other suitable pharmaceutical additives such as
- 15 solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo-regulators, or the like. Examples of liquid carriers suitable for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose
- 20 solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) or their derivatives, or oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier may also be an oily ester such as ethyl oleate or isopropyl myristate.

- Compositions of the invention which are sterile solutions or suspensions are
- 25 suitable for intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions may also be administered intravenously. Inventive compositions suitable for oral administration may be in either liquid or solid composition form.


- Advantageously, compounds of formula I may be used for the identification or determination of the absorption or metabolism of an indolylalkylamine derivative.
- 30 Accordingly, the present invention provides a method for the determination of the metabolism of a (1-arylsulfonyl-1H-indol-3-yl)ethylamine derivative which comprises evaluating a test sample for the presence of a compound of formula I.

For a more clear understanding, and in order to illustrate the invention more clearly, specific examples thereof are set forth hereinbelow. The following examples are merely illustrative and are not to be understood as limiting the scope and underlying principles of the invention in any way.

- 5 Unless otherwise stated, all parts are parts by weight. The terms NMR and HPLC designate nuclear magnetic resonance and high performance liquid chromatography, respectively. The term THF designates tetrahydrofuran.

EXAMPLE 1**Preparation of N-(2-{1-[(6-Chloro-imidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}-ethyl)acetamide**

5




A stirred mixture of 2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethylamine hydrochloride, 417 mg, 1.00 mmol) in dichloromethane and triethylamine (0.40 mL, 3.0 mmol) is treated with catalytic 4-dimethylaminopyridine (DMAP) (~ 5 mg) at room temperature under nitrogen. The heterogeneous mixture is treated with acetic anhydride (0.30 mL, 3.2 mmol) and the reaction becomes homogeneous. After 16 h, the reaction is treated with saturated aqueous NaHCO₃ (8 mL) for 0.3 h and then extracted with dichloromethane. The extracts are combined, dried over MgSO₄ and concentrated *in vacuo* to a foam. The foam is treated with 20:80 ethyl acetate:hexane and concentrated *in vacuo* to a solid. This is triturated with ether and filtered. The filtercake is dried to afford the title product as a white solid, 389 mg (92% yield), mp 150-152°C, characterized by CHN elemental analysis and ¹H NMR.

20

EXAMPLE 2**Preparation of {1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}acetic acid**


5



10 A stirred solution of 3-indolylacetic acid (175 mg, 1.00 mmol) in THF is cooled to -78°C under nitrogen and treated portionwise with 2.5 M n-butyllithium in hexanes (0.84 mL, 2.10 mmol) over a 10 min. period. After 1 h at -78°C , the reaction mixture is treated with (6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl chloride (257 mg, 1.00 mmol) in THF, allowed to warm to ambient temperature, stirred for 24 h and concentrated *in vacuo*. The resultant residue is treated with 1 M aq HCl (~2 mL) and

15 water (3 mL) and extracted with dichloromethane. The extracts are combined, dried (MgSO_4) and concentrated *in vacuo*. Chromatography of this residue, eluting with ethyl acetate, affords the title compound as a light tan solid, 32 mg, mp $220\text{--}222^{\circ}\text{C}$ (darkens $> 200^{\circ}\text{C}$), identified by mass spectral and NMR analyses.

20

EXAMPLE 3**Preparation of 3, 4, 5-Triacetoxy-6-(2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethylcarbamoyloxy)tetrahydropyran-2-carboxylic acid methyl ester**

- A solution of (Boc)₂O (1.8 g, 8.3 mmol, 1.2 eq) in CH₃CN is cooled to 0 °C (ice-water bath), treated dropwise with DMAP (203 mg, 1.66 mmol, 0.2 eq) in CH₃CN, stirred for 5 min, treated dropwise with 2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethylamine (2.6 g, 6.9 mmol) in CH₃CN, stirred for 30 min (isocyanate is generated *in situ*) at 0°C, concentrated using rotavapor to remove the CH₃CN and chased with toluene. The resultant residue is dissolved in toluene, treated dropwise with a solution of hydroxyglucuronic ester (2.6 g, 7.7 mmol, 1.1 eq) in toluene followed by triethylamine (1.2 mL), stirred for 2h at 0 °C, allowed to warm to room temperature, stirred for 16h and concentrated to dryness. This residue is purified by column chromatography (20-50 % THF in heptane as eluent) to afford the pure β -anomer of the title product, 2 g (39 % yield) and a mixture of α - and β -anomers (1:1.6), 2.5 g (49 % yield). The anomers are identified by NMR analysis. ¹H NMR (300 MHz, CDCl₃): β -anomer 4: 8.01 (d, 1H, *J* = 4.5 Hz), 7.95-7.91 (m, 1H), 7.53-7.50 (m, 1H), 7.45 (s, 1H), 7.35-7.26 (2H, m), 7.17 (d, 1H, *J* = 4.5 Hz), 5.74 (d, 1H, *J* = 8.1 Hz), 5.36-5.09 (m, 3H), 4.99 (1H, m), 4.19 (d, 1H, *J* = 9.9 Hz), 3.75 (s, 3H), 3.57-3.41 (2H, m), 2.92 (2H, t, *J* = 7.0 Hz), 2.04, 2.03, 2.02 (3s, 9H). MS [M+H]⁺ = 741. α -anomer (200 mg, contains 2% β -anomer) ¹H NMR (300 MHz, CDCl₃): 8.03 (d, 1H, *J* = 4.2 Hz), 7.94-7.91 (m, 1H), 7.56-7.53 (m, 1H),


7.45 (s, 1H), 7.35-7.26 (2H, m), 7.14 (d, 1H, $J = 4.8$ Hz), 6.33 (d, 1H, $J = 3.6$ Hz), 5.52-5.46 (m, 1H), 5.26-5.10 (3H, m), 4.38 (d, 1H, $J = 10.2$ Hz), 3.74 (s, 3H), 3.57-3.46 (2H, m), 2.92 (2H, t, $J = 7.0$ Hz), 2.03 (3s, 9H).

5

EXAMPLE 4

Preparation of 1-O-[(2-{1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)amino]carbonyl]-beta-D-glucopyranuronic acid

10



A solution of 3,4,5-triacetoxy-6-(2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)carbamoyloxy)tetrahydropyran-2-carboxylic acid methyl ester (1.0 g, 1.35 mmol) in THF is treated with CH_3OH (38.8 mL) and H_2O (10 mL), cooled to 0°C (ice-water bath), treated with a solution of $\text{LiOH} \cdot \text{H}_2\text{O}$ (340 mg, 8.1 mmol, 6 eq) in H_2O (5.5 mL) [0.1 N $\text{LiOH}/\text{MeOH}/\text{THF}/\text{H}_2\text{O}$] and stirred at 0°C for 2 h under N_2 atmosphere. Progress of the deprotection is monitored via reversed-phase TLC ($\text{SiO}_2\text{-C18}$ $\text{MeCN}/\text{H}_2\text{O}$, 3/7). The reaction mixture is diluted with 150 mL of H_2O , neutralized by the addition of 10 g of amberlite-120 (plus) cation exchange material (H^+ form) and filtered. The filtrate is concentrated under reduced pressure to an aqueous suspension. This suspension is freeze dried and lyophilized to give the title product, 700 mg (86% yield). Further purification by silica gel column chromatography [$\text{CHCl}_3/\text{CH}_3\text{OH}/\text{H}_2\text{O}$ (7:3:0.5) as a eluent] provides the title product, 310 mg, 98% pure, identified by mass spectral and NMR analyses. ^1H NMR (300 MHz, $\text{DMSO-}d_6$): 8.31 (d, 1H, $J = 4.5$ Hz), 7.94-7.91 (m, 1H), 7.82 (s, 1H), 7.69 (d, 1H, $J = 4.2$ Hz), 7.64-7.57 (m, 2H), 7.39-7.27 (m, 2H), 5.31 (d, 1H, $J = 8.1$ Hz), 3.69 (d, 1H, $J = 9.0$ Hz), 3.37-3.13 (m, 5H), 2.82 (t, 2H, $J = 7.0$ Hz); ^{13}C (75 MHz, $\text{DMSO-}d_6$): 170.6, 155.4, 155.3, 152.3, 139.2, 134.9, 131.6, 125.7, 124.5, 124.4, 121.1,

121.1, 120.7, 118.8, 116.6, 113.8, 95.5, 76.6, 76.5, 72.8, 72.0, 25.2; LC/MS (ESI) retention time = 35.12, $[M+H]^+$ = 600.7.

The α -anomer (57 mg) is obtained in the same manner described above, identified by HPLC and mass spectral analyses. LC/MS (ESI) retention time = 27.11 min, $[M+H]^+$ = 600.8.

EXAMPLE 5

Comparative Evaluation of 5-HT6 Binding Affinity of Test Compounds

10

The affinity of test compounds for the serotonin 5-HT6 receptor is evaluated in the following manner. Cultured Hela cells expressing human cloned 5-HT6 receptors are harvested and centrifuged at low speed (1,000 x g) for 10.0 min to remove the culture media. The harvested cells are suspended in half volume of fresh physiological phosphate buffered saline solution and recentrifuged at the same speed. This operation is repeated. The collected cells are then homogenized in ten volumes of 50 mM Tris.HCl (pH 7.4) and 0.5 mM EDTA. The homogenate is centrifuged at 40,000 x g for 30.0 min and the precipitate is collected. The obtained pellet is resuspended in 10 volumes of Tris.HCl buffer and recentrifuged at the same speed. The final pellet is suspended in a small volume of Tris.HCl buffer and the tissue protein content is determined in aliquots of 10-25 μ l volumes. Bovine Serum Albumin is used as the standard in the protein determination according to the method described in Lowry et al., *J. Biol. Chem.*, 193:265 (1951). The volume of the suspended cell membranes is adjusted to give a tissue protein concentration of 1.0 mg/ml of suspension. The prepared membrane suspension (10 times concentrated) is aliquoted in 1.0 ml volumes and stored at -70° C until used in subsequent binding experiments.

20

25

Binding experiments are performed in a 96 well microtiter plate format, in a total volume of 200 μ l. To each well is added the following mixture: 80.0 μ l of incubation buffer made in 50 mM Tris.HCl buffer (pH 7.4) containing 10.0 mM $MgCl_2$ and 0.5 mM EDTA and 20 μ l of $[^3H]$ -LSD (S.A., 86.0 Ci/mmol, available from Amersham Life Science), 3.0 nM. The dissociation constant, K_D of the $[^3H]$ -LSD at the human serotonin 5-HT6 receptor is 2.9 nM, as determined by saturation binding with

30

increasing concentrations of [³H]LSD. The reaction is initiated by the final addition of 100.0 µl of tissue suspension. Nonspecific binding is measured in the presence of 10.0 µM methiothepin. The test compounds are added in 20.0 µl volume.

The reaction is allowed to proceed in the dark for 120 min at room temperature, at which time, the bound ligand-receptor complex is filtered off on a 96 well unifilter with a Packard Filtermate[®] 196 Harvester. The bound complex caught on the filter disk is allowed to air dry and the radioactivity is measured in a Packard TopCount[®] equipped with six photomultiplier detectors, after the addition of 40.0µl Microscint[®]-20 scintillant to each shallow well. The unfilter plate is heat-sealed and counted in a PackardTopCount[®] with a tritium efficiency of 31.0%.

Specific binding to the 5-HT₆ receptor is defined as the total radioactivity bound less the amount bound in the presence of 10.0µM unlabeled methiothepin. Binding in the presence of varying concentrations of test compound is expressed as a percentage of specific binding in the absence of test compound. The results are plotted as log % bound versus log concentration of test compound. Nonlinear regression analysis of data points with a computer assisted program Prism[®] yielded both the IC₅₀ and the K_i values of test compounds with 95% confidence limits. A linear regression line of data points is plotted, from which the IC₅₀ value is determined and the K_i value is determined based upon the following equation:

$$K_i = IC_{50} / (1 + L/K_D)$$

where L is the concentration of the radioactive ligand used and K_D is the dissociation constant of the ligand for the receptor, both expressed in nM.

Using this assay, the following K_i values are determined and compared to those values obtained by representative compounds known to demonstrate binding to the 5-HT₆ receptor. The data are shown in Table I, below.

Table I

Test Compound (Ex. No.)	5-HT6 Binding Ki (nM)
1	26
2	248
4	


<u>Comparative Examples</u>	5-HT6 Binding Ki (nM)
Clozapine	6.0
Loxapine	41.4
Bromocriptine	23.0
Methiothepin	8.3
Mianserin	44.2
Olanzapine	19.5

As can be seen from the results set forth above, the compounds of the present invention demonstrate significant affinity for the 5-HT6 receptor.

What is claimed is:


1. A compound of formula I

5



(I)

wherein

- Q is CO₂R₅ or CH₂NR₆COR₇;
- 10 R₁ is H or C₁-C₆alkyl;
- R₂ is an aryl or heteroaryl group each optionally substituted or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
- 15 R₃ and R₄ are each independently H, halogen, CN, OCO₂R₈, CO₂R₉, CONR₁₀R₁₁, CNR₁₂NR₁₃R₁₄, SO_mR₁₅, NR₁₆R₁₇, OR₁₈, COR₁₉ or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₆cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R₅ and R₆ are each independently H or C₁-C₆alkyl;
- R₇ is C₁-C₆alkyl or  ;
- 20 m is 0 or an integer of 1 or 2;
- R₈, R₉, R₁₅ and R₁₉ are each independently H or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₆cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;


R_{10} , R_{11} and R_{18} are each independently H or a C_1 - C_6 alkyl, aryl or heteroaryl group each optionally substituted or R_{10} and R_{11} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and

R_{12} , R_{13} , R_{14} , R_{16} and R_{17} are each independently H or a C_1 - C_4 alkyl, aryl or heteroaryl group each optionally substituted; or R_{13} and R_{14} or R_{16} and R_{17} may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein R_1 , R_3 and R_4 are H.

3. The compound according to claim 1 or claim 2 wherein R_2 is an imidazolyl or imidazothiazolyl group each optionally substituted.

4. The compound according to any one of claims 1 to 3 wherein Q is



5. The compound according to claim 1 selected from the group consisting of:

N -(2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)acetamide;
 $1-O$ -{[(2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)amino]carbonyl}-beta-D-glucopyranuronic acid;
 {1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}acetic acid;
 N -[(1-{[4-chloro-2-(methylthio)-1H-imidazol-5-yl]sulfonyl}-1H-indol-3-yl)methyl]acetamide;
 a stereoisomer thereof; and
 a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5 which is N-(2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)acetamide.

7. The compound according to claim 5 which is 1-O-[[2-{1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl}ethyl)amino]carbonyl]-beta-D-glucopyranuronic acid.

8. A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT₆ receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I according to any one of claims 1 to 7.

9. The method according to claim 8 wherein said disorder is selected from the group consisting of a neurodegenerative disorder; an anxiety disorder; and a cognitive disorder.

10. The method according to claim 9 wherein said anxiety or cognitive disorder is selected from the group consisting of attention deficit disorder; obsessive compulsive disorder; and general anxiety disorder.

11. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I according to any one of claims 1 to 7.

12. A method for the determination of the metabolism of a (1-arylsulfonyl-1H-indol-3-yl)ethylamine derivative which comprises evaluating a test sample for the presence of a compound of formula I according to any one of claims 1 to 7.

13. The use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of a neurodegenerative disorder, an anxiety disorder or a cognitive disorder.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/021852

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/12 C07D417/14 A61K31/4045 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 03/053433 A (WYETH) 3 July 2003 (2003-07-03) the whole document -----	1-13
Y	US 6 187 805 B1 (PINEIRO JOSE LUIS CASTRO ET AL) 13 February 2001 (2001-02-13) the whole document -----	1-13
Y	A. SLASSI ET AL.: "Recent progress in the 5-HT6 receptor antagonists for the treatment of CNS diseases" EXPERT OPIN. THER. PATENTS, vol. 12, no. 4, 2002, pages 513-527, XP002350180 page 520 ----- -/--	1-13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 October 2005

Date of mailing of the international search report

07/11/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2005/021852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 16 18 865 A1 (SUMITOMO CHEMICAL COMPANY LTD; SUMITOMO CHEMICAL CO. LTD., OSAKA) 30 April 1970 (1970-04-30) examples	1,11
X	----- DATABASE WPI Section Ch, Week 196800 Derwent Publications Ltd., London, GB; Class B00, AN 1966-34623F XP002350722 & JP 43 024418 B (SUMITOMO CHEMICAL INDUSTRIES CO LIM) 1968 abstract	1,11
X	----- V. LECLERC ET AL.: "Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninerbicbinding sites MT3" J. MED. CHEM., vol. 45, no. 9, 2002, pages 1853-59, XP002350181 compound 2A	1,11
X	----- SAKAMOTO T ET AL: "Synthesis of ethoxyethynylarenes by the palladium-catalyzed reaction of aryl iodides with ethoxy(trialkylstannyl)acetylenes" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 42, no. 10, 1994, pages 2032-2035, XP002269345 ISSN: 0009-2363 example 4m	1
P,X	----- WO 2005/009958 A (PLEXXIKON, INC; ARNOLD, JAMES; ARTIS, DEAN, R; HURT, CLARENCE; IBRAHIM) 3 February 2005 (2005-02-03) pages 184-194	1,11
P,X	----- WO 2005/040112 A (OXAGEN LIMITED; MIDDLEMISS, DAVID; ASHTON, MARK, RICHARD; BOYD, EDWARD) 6 May 2005 (2005-05-06) examples	1,11
P,X	----- WO 2004/078719 A (ONO PHARMACEUTICAL CO., LTD; IWAHASHI, MAKI; NAGANAWA, ATSUSHI; NISHIY) 16 September 2004 (2004-09-16) examples	1,11

Information on patent family members

International Application No

PCT/US2005/021852

Form PCT/ISA/210 (patent family annex) (January 2004)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2005/021852

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 43024418	B	---	

WO 2005009958	A	03-02-2005	NONE
WO 2005040112	A	06-05-2005	NONE
WO 2004078719	A	16-09-2004	NONE